| P2093 | author name string | Hans de Groot | |
| | Paul L P Brand | |
| | Erik-Jonas van de Griendt | |
| | Mariska K Tuut | |
| P2860 | cites work | Sublingual immunotherapy for asthma | Q24187736 |
| | Injection allergen immunotherapy for asthma | Q24236566 |
| | Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group | Q24809542 |
| | Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Q27860973 |
| | Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews | Q29547775 |
| | GRADE guidelines: 2. Framing the question and deciding on important outcomes. | Q54771670 |
| | Sub-lingual immunotherapy: world allergy organization position paper 2009. | Q55527154 |
| | Two year follow-up of immunological response in mite-allergic children treated with sublingual immunotherapy. Comparison with subcutaneous administration | Q62130007 |
| | Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study | Q67235010 |
| | A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. I. Clinical results | Q68876155 |
| | A controlled trial of hyposensitization with adsorbed tyrosine Dermatophagoides pteronyssinus antigen in childhood asthma: in vivo aspects | Q70361437 |
| | Immunotherapy in allergy to dog: a double-blind clinical study | Q71417206 |
| | The value of hyposensitization therapy for bronchial asthma in children--a 14-year study | Q72123648 |
| | Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study | Q72996277 |
| | A controlled trial of immunotherapy for asthma in allergic children | Q73020915 |
| | Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial | Q73297911 |
| | Comparison between the use of adsorbed and aqueous immunotherapy material in Dermatophagoides pteronyssinus sensitive asthmatic children | Q73303073 |
| | Immunomodulation during sublingual therapy in allergic children | Q73481524 |
| | Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children | Q73594077 |
| | Value of hyposensitization therapy for perennial bronchial asthma in children | Q79124927 |
| | [Sublingual immunotherapy with allergenic extract of Dermatophagoides pteronyssinus in asthmatic children] | Q81582925 |
| | Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multi-center, double-blind, randomized, and placebo-controlled study in Taiwan | Q82223243 |
| | Allergic rhinitis is associated with poor asthma control in children with asthma | Q83167837 |
| | Clinical efficacy of house dust mite-specific immunotherapy in asthmatic children | Q83182665 |
| | GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables | Q29547885 |
| | Sublingual immunotherapy in asthma and rhinoconjunctivitis; systematic review of paediatric literature | Q33204109 |
| | Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method | Q33255883 |
| | Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review | Q34335462 |
| | e-Monitoring of Asthma Therapy to Improve Compliance in children using a real-time medication monitoring system (RTMM): the e-MATIC study protocol | Q34628486 |
| | Grading recommendations in clinical practice guidelines: randomised experimental evaluation of four different systems. | Q34629305 |
| | Failure of hyposensitisation in treatment of children with grass-pollen asthma. | Q34747387 |
| | The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis | Q35005943 |
| | The efficacy and safety of subcutaneous immunotherapy in mite-sensitized subjects with asthma: a meta-analysis | Q35412178 |
| | Sublingual Immunotherapy for Asthmatic Children Sensitized to House Dust Mite: A Meta-Analysis | Q36194445 |
| | Allergen immunotherapy for the treatment of allergic rhinitis and/or asthma: an umbrella review | Q36369716 |
| | Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. | Q36977154 |
| | Allergic rhinoconjunctivitis in children | Q36997007 |
| | An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice | Q37522916 |
| | Efficacy analysis of three-year subcutaneous SQ-standardized specific immunotherapy in house dust mite-allergic children with asthma | Q37575153 |
| | Problematic severe asthma in children, not one problem but many: a GA2LEN initiative | Q37769356 |
| | Comorbidities of asthma during childhood: possibly important, yet poorly studied | Q37798633 |
| | A control model to evaluate pharmacotherapy for allergic rhinitis in children | Q38084580 |
| | Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison | Q38096138 |
| | Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review | Q38104712 |
| | Getting the basics right resolves most cases of uncontrolled and problematic asthma | Q38512040 |
| | Assessing the efficacy of immunotherapy with a glutaraldehyde-modified house dust mite extract in children by monitoring changes in clinical parameters and inflammatory markers in exhaled breath. | Q39084557 |
| | Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy | Q39309227 |
| | Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma | Q39515670 |
| | Assessment of problematic severe asthma in children | Q39823053 |
| | Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. | Q40403475 |
| | Prevalence and severity of asthma, rhinitis, and atopic eczema in 13- to 14-year-old schoolchildren from the northeast of England | Q40603145 |
| | Sublingual immunotherapy and influence on urinary leukotrienes in seasonal pediatric allergy | Q41705273 |
| | Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-specific Lung Disease Study Group | Q42061114 |
| | Efficacy of immunotherapy for treatment of allergic asthma in children | Q42916699 |
| | Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial | Q42972511 |
| | Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study | Q43646876 |
| | Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate | Q44680424 |
| | Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria-induced respiratory allergy: a randomized controlled trial | Q44961338 |
| | The minimally important difference of the Asthma Control Test | Q46118096 |
| | Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization | Q47702181 |
| | Effect of an intranasal corticosteroid on exercise induced bronchoconstriction in asthmatic children. | Q48518713 |
| | A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen. | Q52942005 |
| | A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes. | Q53243033 |
| | Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. | Q53459403 |
| | Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. | Q54420300 |
| | [Sublingual immunotherapy in children with asthma or rhinoconjunctivitis: not enough evidence because of poor quality of the studies; a systematic review of literature] | Q54544028 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| | systematic review | Q1504425 |
| | asthma | Q35869 |
| | disease progression | Q86758334 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | e016326 | |
| P577 | publication date | 2017-12-28 | |
| P1433 | published in | BMJ Open | Q17003470 |
| P1476 | title | Applicability of evidence from previous systematic reviews on immunotherapy in current practice of childhood asthma treatment: a GRADE (Grading of Recommendations Assessment, Development and Evaluation) systematic review | |
| P478 | volume | 7 | |